Back to Search
DR. GIROLAMO JERRY ARPINO D.O.
D.O.
Internal Medicine Physician
NPI: 1578710265IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
5232(AZ)
Sleep Medicine (Internal Medicine) Physician
Internal Medicine — Sleep Medicine
Code: 207RS0012X
5232(AZ)
Education
OTHER
Class of 2005
Research & Publications (17)
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
PMID 18216219·Endocr Rev·2008
6-review
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
PMID 17470737·J Natl Cancer Inst·2007
7-preclinical
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
PMID 16273359·Cancer Chemother Pharmacol·2005
6-review
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
PMID 16145046·J Natl Cancer Inst·2005
8-other
Premalignant and in situ breast disease: biology and clinical implications.
PMID 16172443·Ann Intern Med·2005
8-other
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
PMID 16234531·J Clin Oncol·2005
6-review
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
PMID 16236516·Breast·2005
6-review
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
PMID 15980993·Breast Cancer Res Treat·2005
8-other
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
PMID 15837971·J Clin Oncol·2005
8-other
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
PMID 16000569·Clin Cancer Res·2005
1-meta
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
PMID 15084238·Breast Cancer Res·2004
4-observational
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
PMID 15355892·Clin Cancer Res·2004
8-other
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
PMID 12743151·J Clin Oncol·2003
8-other
Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer.
PMID 12562650·Ann Oncol·2003
3-trial
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
PMID 12381900·Oncology·2002
3-trial
Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome.
PMID 12001107·Cancer·2002
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 9171 W THUNDERBIRD RD STE 101
PEORIA, AZ 85381 - Phone
- (623) 877-0100
Quick Facts
- NPI
- 1578710265
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 21
- Publications
- 17
Are you this provider?
Claim Your Profile